您好,歡迎訪問中山大學腫瘤防治中心官方網站!
內部網 職工郵箱 圖書館 OA系統 醫生門戶 English
院士風采 首席專家 臨床專家 科研學者 客座教授 人才名錄 護理專家
首頁
  • 謝方云

    職務:
    職稱:教授、主任醫師、博士生導師
    專長:鼻咽癌、舌癌、喉癌、下咽癌、牙齦癌、扁桃體癌等頭頸腫瘤綜合治療
    一、基本情況
    職稱:教授、主任醫師、博士生導師
    專業特長:鼻咽癌、舌癌、喉癌、下咽癌、牙齦癌、扁桃體癌等頭頸腫瘤綜合治療
    專家門診時間:越秀院區:周二下午、周三上午 黃埔院區:周四上午
    主攻方向如下:①鼻咽癌的調強放射治療、圖像引導放射治療及自適應放療;②鼻咽癌調強放射治療及個體化精準治療;③頭頸部腫瘤的調強放射治療及綜合治療

    二、學習及工作經歷
    1980.09-1985.07  湖南醫學院   臨床醫學   本科   獲學士學位
    1985.07-2002.08 中山大學腫瘤防治中心  放療科 住院醫師、主治醫師
    1990.09-1994.07  中山醫科大學   腫瘤學  獲碩士學位
    2002.08-至今 中山大學腫瘤防治中心  放療科 副主任醫師、主任醫師、教授

    三、學術兼職
    廣東省醫師協會放射治療專業委員會副主任委員
    廣東省醫師協會放射治療專業委員會頭頸腫瘤專業組組長
    粵港澳大灣區放射治療醫師聯盟副主任
    華人腫瘤放射治療協作組第一屆放射免疫工作委員會常委

    四、獲獎情況
    (1) 鼻咽癌精準診療方案的建立與應用 2020年 教育部高??萍歼M步獎一等獎
    (2) 提高鼻咽癌療效的關鍵技術與應用 2020年 廣東省醫學科學技術獎一等獎
    (3) 鼻咽癌診療關鍵策略研究與應用  2015年 國家科學技術進步獎二等獎 
    (4) 鼻咽癌個體化治療研究與應用 2014年 中華醫學科技獎一等獎
    (5) 鼻咽癌個體化治療研究與應用 2014年 高等教育部科技進步獎一等獎
    (6) 鼻咽癌個體化治療研究與應用 2014年 廣東省科學技術獎勵一等獎
    一、基本情況
    職稱:教授、主任醫師、博士生導師
    專業特長:鼻咽癌、舌癌、喉癌、下咽癌、牙齦癌、扁桃體癌等頭頸腫瘤綜合治療
    專家門診時間:越秀院區:周二下午、周三上午 黃埔院區:周四上午
    主攻方向如下:①鼻咽癌的調強放射治療、圖像引導放射治療及自適應放療;②鼻咽癌調強放射治療及個體化精準治療;③頭頸部腫瘤的調強放射治療及綜合治療

    二、學習及工作經歷
    1980.09-1985.07  湖南醫學院   臨床醫學   本科   獲學士學位
    1985.07-2002.08 中山大學腫瘤防治中心  放療科 住院醫師、主治醫師
    1990.09-1994.07  中山醫科大學   腫瘤學  獲碩士學位
    2002.08-至今 中山大學腫瘤防治中心  放療科 副主任醫師、主任醫師、教授

    三、學術兼職
    廣東省醫師協會放射治療專業委員會副主任委員
    廣東省醫師協會放射治療專業委員會頭頸腫瘤專業組組長
    粵港澳大灣區放射治療醫師聯盟副主任
    華人腫瘤放射治療協作組第一屆放射免疫工作委員會常委

    四、獲獎情況
    (1) 鼻咽癌精準診療方案的建立與應用 2020年 教育部高??萍歼M步獎一等獎
    (2) 提高鼻咽癌療效的關鍵技術與應用 2020年 廣東省醫學科學技術獎一等獎
    (3) 鼻咽癌診療關鍵策略研究與應用  2015年 國家科學技術進步獎二等獎
    (4) 鼻咽癌個體化治療研究與應用 2014年 中華醫學科技獎一等獎
    (5) 鼻咽癌個體化治療研究與應用 2014年 高等教育部科技進步獎一等獎
    (6) 鼻咽癌個體化治療研究與應用 2014年 廣東省科學技術獎勵一等獎

    五、主持科研項目
    ①國家自然科學基金重點項目 cdh1(FZR1)磷酸化新點被調控的機理,對功能的影響及其意義(2009-2013年,第2負責人)
    ②國家自然科學基金面上項目  Fli-1靶向上調VEGF-C促進鼻咽癌轉移的分子機制和臨床意義研究(2017-2020年 第1負責人)
    ③廣東省自然科學基金 Fli-1靶向調控VEGF-C促進鼻咽癌生長和轉移的研究(2017-2020,第1負責人)
    ④廣東省科學技術廳 多西他賽加順鉑(TP)對比單藥順鉑(DDP)的同期化療聯合調強放療治療高危局部區域晚期鼻咽癌的隨機對照II期臨床研究(2016-2018年,第1負責人)
    ⑤中山大學5010項目 調強放療加或不加同期化療治療II期鼻咽癌的非劣效性、隨機對照、多中心III期臨床研究(2015-2025年,第1負責人)

    六、第一及或通訊作者發表SCI文章
    1. Xiang-Bo Wan, Rou Jiang, Fang-Yun Xie (Co-first authors), Zhen-Yu Qi, Ai-Ju Li, Wei-Jun Ye, Yi-Jun Hua, Yu-Liang Zhu, Xiong Zou, Ling Gao, Hai-Qiang Mai, Xiang Guo, Ming-Huang Hong, Ming Yuan Che. Endoscope—guided interstitial intensity-modulated brachytherapy and intracavitary brachytherapy as boost radiation for primary early T stage nasopharyngeal carcinoma. PLoS One 2014;9;e90048.(IF 2.806)
    2. Xiao-Bin Lv, Fangyun Xie (Co-first authors), Kaishun Hu, Yuanzhong Wu, Lin-Lin Cao, Xia Han, Yi Sang, Yi-Xin Zeng, and Tiebang Kang. Damaged DNA-binding protein 1(DDB1) interacts with Cdhl and modulates the function of APC/CCdhl. J Biol Chem 2010; 285:18234-18240.(IF 4.125)
    3. Pu-Yun OuYang, MD, Lu-Ning Zhang, MD, Jie Tang, MD, Xiao-Wen Lan, MD, Yao Xiao, MD, Yuan-Hong Gao, MD, and Fang-Yun Xie, Md. Evaluation of Body Mass Index and Survival of Nasopharyngeal Carcinoma by Propensity-Matched Analysis: An Observational Case-Control Study. Medicine (Baltimore)2016;95:e2380(IF 1.803)
    4. Lu-Ning Zhang, Yuan-Hong Gao, Xiao-Wen Lan, Jie Tang, Zhen Su, Jun Ma, Wuguo Deng,Pu-Yun OuYang, Fang-Yun Xie. Propensity score matching analysis of cisplatin-based concurrent chemotheraoy in low risk nasopharyngeal carcinoma in the intensity-modulated radiotheraphy era. Oncotarget 2015;6:44019-44029(IF 5.168)
    5. P-Y OuYang, L-N Zhang, X-W Lan, C Xie, W-W Zhang, Q-X Wang, Z Su, J Tang and F-Y Xie. The significant survival advantage of female sex in nasopharyngeal carcinoma:a propensity-matched analysis. Br J Cancer 2015;112:1554-1561(IF 6.176)
    6. Lu-Ning Zhang, Jie Tang, Xiao-Wen Lan, Pu-Yun OuYang, Fang-Yun Xie. Pretreatment anemia and survival in nasopharyngeal carcinoma. Tumour Biol 2015(IF 3.65)
    7. Zhen Su, Yan-Ping Mao, Jie Tang, Xiao-Wen Lan, Pu-Yun Ouyang, Fang-Yun Xie. Long-term outcomes of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma treated with IMRT:a retrospective study. Tumour Biol 2015(IF 3.65)
    8. Lu-Ning Zhang, Yuan-Hong Gao, Xiao-Wen Lan, Jie Tang, Pu-Yun OuYang, Fang-Yun Xie. Effect of taxanes-based induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: A large scale propensity-matched study. Oral Oncol 2015;51:950-956(IF 4.794)
    9. Zhen Su, Yan-Ping Mao, Pu-Yun OuYang, Jie Tang, Xiao-Wen Lan and Fang-Yun Xie. Leucopenia and treatment efficacy in advanced nasopharyngeal carcinoma. BMC Cancer 2015;15:429(IF 3.288)
    10. Zhen Su, Yan-Ping Mao, Pu-Yun OuYang, Jie Tang, Fang-Yun Xie. Initial Hyperleukocytosis and Neutrophilia in Nasopharyngeal Carcinoma: Incidence and Prognostic Impact. PLoS One2015;10:e0136752(IF 2.806)
    11. Xue-Xia Liang, Qun Li, Zhen Su, Xiao-Wen Lan, Pu-Yun OuYang, Yan-Ping Mao, Ding-Bo Shi, Wu-Guo Deng, Zhi-Bin Cheng, Si-Yang Wang, Fang-Yun Xie. Significant prognostic impact of chemoradiatherapy-induced hemoglobin decrease on treatment outcomes of nasopharyngeal carcinoma. J Cancer 2015;6;:502-510(IF 2.916)
    12. Pu-Yun OuYang, Zhen Su, Jie Tang, Xiao-Wen Lan, Yan-Ping Mao,Wuguo Deng, Fang-Yun Xie. Diabetes,Prediabetes and the Survival of Nasopharyngeal Carcinoma:A Study of 5,860 Patients. PLoS One2014;9:e111073(IF 2.806)
    13. Xuexia Liang, Dingbo Shi, Jingping Yun, Yanping Mao,Puyun Ouyang, Zhen Su, Jia Fu, Jinghui Hou, Wuguo Deng and Fangyun Xie. Friend leukemia virus integration 1 expression has prognostic significance in nasopharyngeal carcinoma. Transl Oncol 2014;7:493-502(IF 3.025)
    14.P.Y.OuYang,C.Xie,Y.P.Mao,Y.Zhang,X.X.Liang,Z.Su,Q.Liu&F.Y.Xie. Significant efficacies of neoadjuvant and adjuvant chemotherapy for nasopharyngeal carcinoma by meta-analysis of published literature-based randomized, controlled trials. Ann Oncol 2013;24:2136-2146(IF 11.855)
    15. P-Y OuYang, Z Su, Y-P Mao, Q Liu and F-Y Xie. Prognostic value of ABO blood group in southern Chinese patients with established nasopharyngeal carcinoma. Br J Cancer 2013;109:2462-2466(IF 6.176)
    16. Pu-Yun OuYang, Zhen Su, Yan-Ping Mao, Xue-Xia Liang, Qing Liu, Wu-Guo Deng, and Fang-Yun Xie. Prognostic impact of family history in southern Chinese patients with undifferentiated nasopharyngeal carcinoma. Br J Cancer 2013;109:788-794(IF 6.176)
    17. P-Y OuYang, Z Su,X-H Ma, Y-P Mao, M-Z Liu and F-Y Xie. Comparison of TNM staging systems for nasopharyngeal carcinoma, and proposal of a new staging system. Br J Cancer 2013;109:2987-29979(IF 6.176)
    18. P-Y OuYang, Z Su, Y-P Mao, X-X Liang, Q Liu and F-Y Xie. Prognostic impact of cigarette smoking on the survival of patients with established nasopharyngeal carcinoma.Cancer Epidemiol Biomarkers Prev 2013;22:2285-2294(IF 6.176)
    19. Pu-Yun OuYang, Zhen Su, Yan-Ping Mao, Wuguo Deng, Fang-Yun Xie. Combination of EGFR-TKIs and Chemotherapy as First-Line Therapy for Advanced NSCLC:A Meta-Analysis. PLoS One2018;8:e79000(IF 2.806)
    20. Xin Wang, Yi Liang, Qiong Chen, Hui-Min Xu, Nan Ge,Rong-Zhen Luo, Jian-Yong Shao, Zhi-Wei He, Yi-Xin Zeng, Tiebang Kang, Jing-Ping Yun &Fangyun Xie. Prognostic significance of SOX2 exoression in nasopharyngeal carcinoma. Cancer Invest 2012;30:79-85(IF 2.007)
    21. Hui-Min Xu, Yi Liang, Qiong Chen, Qi-Nian Wu, Yun-Miao Guo, Guo-Ping Shen, Ru-Hua Zhang, Zhi-Wei He, Yi-Xin Zeng, Fang-Yun Xie, and Tie-Bang Kang. Correlation of Skp2 overexpression to prognosis of patients with nasopharyngeal carcinoma from South China. Chin J Cancer2011;30:204-212(IF 4.111)
    22. Pu-Yun OuYang, Dingbo Shi, Rui Sun, Yu-Jia Zhu, Yao Xiao,Lu-Ning Zhang, Xu-Hui Zhang, Ze-Ying Chen, Xiao-Wen Lan, Jie Tang, Yuan-Hong Gao, Jun Ma, Wuguo Deng, Fang-Yun Xie. Effect of intensity-modulated radiotherapy versus two-dimensional conventional radiotherapy alone in nasopharyngeal carcinoma. Oncotarget. 2016 Apr 4.(IF 5.168)
    23. Zhen Su, Yan-Ping Mao, Jie Tang, Xiao-Wen Lan, Pu-Yun OuYang, Fang-Yun Xie. Long-term outcomes of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma treated with IMRT: a retrospective study. Tumor Biol. 2016 Apr;37(4):4429-38(IF 3.65)
    24. Pu-Yun OuYang, Zhuo-Fei Bi, Lu-Ning Zhang, Kai-Yun You, Yao Xiao, Xiao-Wen Lan, Jie Tang, Xi-Cheng Wang, Wuguo Deng and Fang-Yun Xie. Outcomes of Induction Chemotherapy Plus Intensity-Modulated Radiotherapy (IMRT) Versus IMRT Plus Concurrent Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma: A Propensity Matched Study. Transl Oncol. 2016; 9(4):329-335.(IF 3.025)
    25. Xiao-Wen Lan, Xue-Bin Zou, Yao Xiao, Jie Tang, Pu-Yun OuYang, Zhen Su, Fang-Yun Xie. Retrospective Analysis of the Survival Benefit of Induction Chemotherapy in Stage Iva-b Nasopharyngeal Carcinoma:Plos One.2016;11(8):e0160758.(IF 2.806)
    26. Lei Chen, Chao-Su Hu, Xiao-Zhong Chen, Guo-Qing Hu, Zhi-Bin Cheng, Yan Sun, Wei-Xiong Li, Yuan-Yuan Chen, Fang-Yun Xie, Shao-Bo Liang, Yong Chen, Ting-Ting Xu, Bin Li, Guo-Xian Long, Si-Yang Wang, Bao-Min Zheng, Ying Guo, Ying Sun, Yan-Ping Mao, Ling-Long Tang, Yu-Ming Chen, Meng-Zhong Liu, Jun Ma.Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomiased controlled trial. Lancet Oncol2012;13:163-71(IF 33.9)
    27. Ying Sun, Wen-Fei Li, Nian-Yong Chen, Ning Zhang, Guo-Qing Hu, Fang-Yun Xie (Co-first authors), Yan Sun, Xiao-Zhong Chen, Jin-Gao Li, Xiao-Dong Zhu. Chao-Su Hu, Xiang-Ying Xu, Yuan-Yuan Chen, Wei-Han Hu, Ling Guo, Hao-Yuan Mo, Lei Chen, Yan-Ping Mao, Rui-Sun, Ping Ai, Shao-Bo Liang, Guo-Xian Long, Bao-Min Zhang, Xing-Lai Feng, Xiao-Chang Gong, Ling Li, Chun-Ying Shen, Jian-Yu Xu, Ying Guo, Yu-Ming Chen, Dan Zhang, Li Lin, Ling-Long Tang, Meng-Zhong Liu, Jun Ma. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicenter, randomized controlled trial. Lancet Oncol 2016:1470-2045(IF 33.9)
    28. Xiao-Wen Lan, Yao Xiao, Xue-Bin Zou, Pu-Yun OuYang, Fang-Yun Xie. Outcomes of adding induction chemotherapy to concurrent chemoradiotherapy for stage T3N0-1 nasopharyngeal carcinoma: a propensity-matched study. OncoTargets and Therapy 2017:10 3853-3860(IF 2.3184)
    29. Pu-Yun OuYang, Yao Xiao, Kai-Yun You, Lu-Ning Zhang, Xiao-Wen Lan, Xiao-Min Zhang, Fang-Yun Xie. Validation and comparison of the 7th and 8th edition of AJCC staging systems for non-metastatic nasopharyngeal carcinoma, and proposed staging systems from Hong Kong, Guangzhou, and Guangxi. Oral Oncol 2017; 72: 65-72. (IF 4.794)
    30. Pu-Yun OuYang, Lu-Ning Zhang, Yao Xiao, Xiao-Wen Lan, Xiao-Min Zhang, Jun Ma, Fang-Yun Xie. Validation of published nomograms and accordingly individualized induction chemotherapy in nasopharyngeal carcinoma. Oral Oncol 2017;67:37-45.(IF 4.794)
    31. Zhen Su, Zhan-Wen Guo, Yan-Ping Mao, Jie tang, Xiao-Wen Lan, Fang-Yun Xie, Qun Li. Anal adenocarcinoma requires prophylactic inguinal nodal treatment: Results from a single Chinese institution.  J Cancer 2017 Apr 9;8(6):1097-1102. (IF 2.916)
    32. OuYang PY, Zhang XM, Qiu XS, Liu ZQ, Lu L, Gao YH, Xie FY. A Pairwise Meta-Analysis of Induction Chemotherapy in Nasopharyngeal Carcinoma. Oncol 2019 (IF 5.306)
    33. Zhang Y, Chen L, Hu GQ, Zhang N, Zhu XD, Yang KY, Jin F, Shi M, Chen YP, Hu WH, Cheng ZB, Wang SY, Tian Y, Wang XC, Sun Y, Li JG, Li WF, Li YH, Tang LL, Mao YP, Zhou GQ, Sun R, Liu X, Guo R, Long GX, Liang SQ, Li L, Huang J, Long JH, Zang J, Liu QD, Zou L, Su QF, Zheng BM, Xiao Y, Guo Y, Han F, Mo HY, Lv JW, Du XJ, Xu C, Liu N, Li YQ, Chua MLK, Xie FY, Sun Y, Ma J. Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. N Engl J Med. 2019 Sep 19;381(12):1124-1135. (IF 74.699)
    36.Chen YP, Liu X, Zhou Q, Yang KY, Jin F, Zhu XD, Shi M, Hu GQ, Hu WH, Sun Y, Wu HF, Wu H, Lin Q, Wang H, Tian Y, Zhang N, Wang XC, Shen LF, Liu ZZ, Huang J, Luo XL, Li L, Zang J, Mei Q, Zheng BM, Yue D, Xu J, Wu SG, Shi YX, Mao YP, Chen L, Li WF, Zhou GQ, Sun R, Guo R, Zhang Y, Xu C, Lv JW, Guo Y, Feng HX, Tang LL, Xie FY, Sun Y, Ma J. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet. 2021 Jun 4:S0140-6736(21)01123-5. doi: 10.1016/S0140-6736(21)01123-5.(IF:60.392)


    更新日期:2021年7月7日
訪客通道
員工通道
關注腫瘤醫院
留言建議 ×
一女N男猛挺进肉多片段,农村妇女打野战视频在线观看,欧美肥老太牲交大战,日本熟妇中文无码